Efficacy of fluorouracil combined with paclitaxel and oxaliplatin for the treatment of advanced gastric signet ring cell carcinoma

Table 6 Incidence of adverse events in patients with advanced gastric signet ring cell carcinoma after chemotherapy

Toxicity (NCI-CTCAE v 3.0)	Grade I	Grade II	Grade III	Grade IV	Grade I/II (%)	Grade III/IV (%)
Leukopenia	34	17	14	4	60.0	21.2
Neutropenia	20	13	15	4	38.8	22.4
Anemia	28	9	6	0	43.5	7.1
Thrombocytopenia	13	5	6	1	21.2	8.2
Nausea/vomiting	14	5	0	0	22.4	0
Diarrhea	20	4	0	0	28.2	0
Oral mucositis	5	3	5	0	9.4	5.9
Hepatic injury	29	18	4	0	55.3	4.7
Peripheral neurotoxicity	35	18	9	0	62.4	10.6
Anaphylaxis	0	0	0	0	0	0

NCI-CTCAE v3.0: National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.